DOX can cause cardiotoxicity, cardiomyopathy, and congestive heart failure through inflammatory mechanisms and an increase in IL-8, NFκB, TNFα, monocyte chemotactic protein-1 (MCP-1), and Doxorubicin-mediated activation of NFκB and inflammatory cytokines by the effect of DOX through HMGB1. Here, CCL2 is linked to cardiomyopathy.